Truist Securities Reiterates Buy on PROCEPT BioRobotics, Maintains $49 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has reiterated a 'Buy' rating on PROCEPT BioRobotics (NASDAQ:PRCT) and maintained a price target of $49.
September 13, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated a 'Buy' rating on PROCEPT BioRobotics, maintaining a price target of $49.
The reiteration of a 'Buy' rating by Truist Securities indicates their continued confidence in PROCEPT BioRobotics. The maintained price target of $49 suggests they believe the stock is still undervalued. This could potentially lead to an increase in investor confidence and a positive impact on the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100